Recommended Pages at agn.client.shareholder.com
Allergan - FDA Approves Expanded Use of LAP-BAND® Adjustable Gastric Banding System for Obese Adults
agn.client.shareholder.com — “Allergan - FDA Approves Expanded Use of LAP-BAND® Adjustable Gastric Banding System for Obese Adults” View full resource at agn.client.shareholder.com
Most Recently Shared on February 17, 2011 at 2:13 pm By:
eyeonfda Pharma and Health Lawyer
#FDA Approves Expanded Use of LAP-BAND® Adjustable Gastric Banding System - http://ow.ly/3Ye5u
Allergan - Allergan Receives FDA Approval for OZURDEX(R) as Treatment Option for Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
agn.client.shareholder.com — “Allergan - Allergan Receives FDA Approval for OZURDEX(R) as Treatment Option for Non-Infectious Uveitis Affecting the Posterior Segment of the Eye” View full resource at agn.client.shareholder.com
Most Recently Shared on September 24, 2010 at 8:37 pm By:
eyeonfda Pharma and Health Lawyer
Allergan Gets FDA OK 4 OZURDEX(R) - Trtmnt Option 4 Non-Infectious Uveitis Affecting Posterior Segment of the Eye http://ow.ly/2JA4J
Allergan - Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
agn.client.shareholder.com — “Allergan - Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients” View full resource at agn.client.shareholder.com
Most Recently Shared on September 1, 2010 at 1:27 pm By:
eyeonfda Pharma and Health Lawyer
Allergan Gets FDA Approval 4 LUMIGAN(R) 1st-Line Tx 4 Reduction of Elevated Intraocular Pressure in Glaucoma Patients - http://ow.ly/2xRWT
Allergan - Allergan, Inc. Announces FDA Approval of JUVDERM(R) XC Dermal Filler Formulated with Lidocaine
agn.client.shareholder.com — “Allergan - Allergan, Inc. Announces FDA Approval of JUVDERM(R) XC Dermal Filler Formulated with Lidocaine” View full resource at agn.client.shareholder.com
Most Recently Shared on February 1, 2010 at 4:12 pm By:
eyeonfda Pharma and Health Lawyer
Allergan Announces FDA Approval of JUVÉDERM(R) XC Dermal Filler Formulated with Lidocaine - http://ow.ly/12Bds
Allergan - FDA Designates Fast Track Status for Apaziquone (EOquin(R)) for Bladder Cancer
agn.client.shareholder.com — “Allergan - FDA Designates Fast Track Status for Apaziquone (EOquin(R)) for Bladder Cancer” View full resource at agn.client.shareholder.com
Most Recently Shared on July 21, 2009 at 2:28 pm By:
eyeonfda Pharma and Health Lawyer
FDA Designates Fast Track Status for Allergan's Apaziquone (EOquin(R)) for Bladder Cancer http://bit.ly/Eui6y
